Oral Anti-Diabetic Agents-Review and Updates

References (90)

1. 1 Effects of Intensive Glucose Lowering in Type 2 Diabetes [DOI]
2. 2 Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes [DOI]
3. 3 AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling [DOI]
4. 4 Pharmacologic Therapy for Type 2 Diabetes Mellitus [DOI]
5. 5 Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP [DOI]
6. 6 Metformin in polycystic ovary syndrome: systematic review and meta-analysis [DOI]
7. 7 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes [DOI]
8. 8 Metformin in non-alcoholic steatohepatitis [DOI]
9. 9 Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption [DOI]
10. 10 Principles of pharmacology : the pathophysiologic basis of drug therapy
11. 11 Thiazolidinediones: a new class of antidiabetic drugs [DOI]
12. 12 Sulfonylureas in NIDDM [DOI]
13. 13 Metformin: its botanical background [DOI]
14. 14 Sulfonylurea Induced β-Cell Apoptosis in Cultured Human Islets [DOI]
15. 15 Incidence of lactic acidosis in metformin users. [DOI]
16. 16 Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2 [DOI]
17. 17 Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes* [DOI]
18. 18 A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes [DOI]
19. 19 Glucose Control by the Kidney: An Emerging Target in Diabetes [DOI]
20. 20 Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone [DOI]
21. 21 Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects [DOI]
22. 22 PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome [DOI]
23. 23 Thyrotropin Suppression by Metformin [DOI]
24. 24 Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double‐blind, placebo‐controlled study [DOI]
25. 25 SGLT-2 inhibitors and their potential in the treatment of diabetes [DOI]
26. 26 Effects of SGLT2 inhibitors on cardiovascular outcomes [DOI]
27. 27 Nonhypoglycemic Effects of Thiazolidinediones [DOI]
28. 28 Metabolic and Additional Vascular Effects of Thiazolidinediones [DOI]
29. 29 Metformin Treatment to Prevent Early Puberty in Girls with Precocious Pubarche [DOI]
30. 30 Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells [DOI]
31. 31 Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration [DOI]
32. 32 CD26/dipeptidyl peptidase IV and its role in cancer. [DOI]
33. 33 Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus [DOI]
34. 34 Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans [DOI]
35. 35 The First Approved Agent in the Glitazar’s Class: Saroglitazar [DOI]
36. 36 Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice [DOI]
37. 37 Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
38. 38 Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes [DOI]
39. 39 Evidence for the benefit of exercise therapy in patients with type 2 diabetes [DOI]
40. 40 A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition [DOI]
41. 41 Activation of PPAR-δ in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids [DOI]
42. 42 Gliptin versus a sulphonylurea as add-on to metformin [DOI]
43. 43 Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγnull mice treated with alogliptin [DOI]
44. 44 Pathology of the endocrine pancreas. [DOI]
45. 45 Sitagliptin with metformin: Profile of a combination for the treatment of type 2 diabetes [DOI]
46. 46 Optimisation of the Management of Patients with Coronary Heart Disease and Type 2 Diabetes Mellitus [DOI]
47. 47 Saxagliptin for type 2 diabetes [DOI]
48. 48 431 Limited efficacy of glyburide for glycemic control [DOI]
49. 49 Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment [DOI]
50. 50 Insulin and Hypoglycemic Agents [DOI]
51. 51 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [DOI]
52. 52 Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin [DOI]
53. 53 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [DOI]
54. 54 IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040 [DOI]
55. 55 Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes [DOI]
56. 56 Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [DOI]
57. 57 Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial [DOI]
58. 58 AMP-activated protein kinase, a metabolic master switch: possible roles in Type 2 diabetes [DOI]
59. 59 Oral Antidiabetic Agents [DOI]
60. 60 Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance [DOI]
61. 61 Racial and ethnic differences in glycemic control of adults with type 2 diabetes. [DOI]
62. 62 Therapeutic Roles of Peroxisome Proliferator–Activated Receptor Agonists [DOI]
63. 63 Active sugar transport in health and disease [DOI]
64. 64 Antidiabetic Therapies Affect Risk of Pancreatic Cancer [DOI]
65. 65 The sodium/glucose cotransport family SLC5 [DOI]
66. 66 The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone [DOI]
67. 67 Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy [DOI]
68. 68 A review of the efficacy and safety of oral antidiabetic drugs [DOI]
69. 69 Cardiovascular Outcomes in Trials of Oral Diabetes Medications [DOI]
70. 70 Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial [DOI]
71. 71 Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control [DOI]
72. 72 Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment [DOI]
73. 73 Dipeptidyl Peptidase Inhibits Malignant Phenotype of Prostate Cancer Cells by Blocking Basic Fibroblast Growth Factor Signaling Pathway [DOI]
74. 74 Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes [DOI]
75. 75 Comparative Tolerability Profiles of Oral Antidiabetic Agents [DOI]
76. 76 Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials [DOI]
77. 77 Treating prediabetes with metformin: systematic review and meta-analysis.
78. 78 Treating prediabetes with metformin: systematic review and meta-analysis
79. 79 Update on the Canadian Diabetes Association 2008 clinical practice guidelines.
80. 80 Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients [DOI]
81. 81 Lipid Lowering and Antioxidant Effect of Miglitol in Triton Treated Hyperlipidemic and High Fat Diet Induced Obese Rats [DOI]
82. 82 Effect of Cephalexin on the Pharmacokinetics of Metformin in Healthy Human Volunteers [DOI]
83. 83 Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes [DOI]
84. 84 Understanding GLP-1 Analogs and Enhancing Patient Success [DOI]
85. 85 Efficacy and Safety of Sitagliptin in the Treatment of Type 2 Diabetes [DOI]
86. 86 The restrictions on possible mechanisms of intestinal transport of sugars
87. 87 Facts, fantasies and fun in epithelial physiology [DOI]
88. 88 Drugs In Pipeline For Type-2 Diabetes [DOI]
89. 89 Oral hypoglycaemic drugs and newer agents use in Type 2 diabetes mellitus [DOI]
90. 90 Do Incretin-Based Therapies Cause Acute Pancreatitis? [DOI]

Cited by 21

Showing 7 of 21 known citations — external sources report more than can currently be individually listed.

Related research

• Clinical Case Series on Assessment of Therapeutic Efficacy of Saroglitazar in MASLD Patients — shares topic coverage
• Saroglitazar as a Metabolic Modulator: A Critical Narrative Review of PPAR-Driven Therapeutic Actions — shares topic coverage
• Atherogenic Diabetic Dyslipidemia — shares topic coverage
• Impact of Saroglitazar as an Add-on Therapy to Rosuvastatin in Patients with Diabetic Dyslipidemia– A Prospective, Single Centre, Observational Study in Indian Patients — shares topic coverage
• Use of Therapy Diary as a Method for Monitoring and Improving Adherence to Metformin Therapy in Diabetic Patients — shares topic coverage